ArriVent BioPharma announces $75 million public offering

NEWTOWN SQUARE, Pa. - ArriVent BioPharma, Inc. (NASDAQ:AVBP), a clinical-stage biopharmaceutical company with a market capitalization of approximately $745 million, announced Tuesday its intention to offer $75 million of common stock and pre-funded warrants in an underwritten public offering. The stock, currently trading at $20.89, appears overvalued according to InvestingPro Fair Value calculations.

The clinical-stage biopharmaceutical company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the total securities on the same terms. Goldman Sachs & Co. LLC, Citigroup and Guggenheim Securities are serving as joint book-running managers for the offering.

ArriVent intends to use the net proceeds to support development activities for firmonertinib, its lead development candidate, and other pipeline programs, as well as for working capital and general corporate purposes. The company maintains a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 14.3x, according to InvestingPro data.

The offering is being made pursuant to an automatic shelf registration statement on Form S-3ASR filed with the Securities and Exchange Commission on February 3, 2025. A preliminary prospectus supplement and accompanying base prospectus will be filed with the SEC.

ArriVent focuses on identifying, developing, and commercializing medicines for cancer patients. The company is working to advance firmonertinib and develop a pipeline of novel therapeutics including next-generation antibody drug conjugates.

The announcement, based on a company press release, noted that the offering is subject to market and other conditions. The final terms will be disclosed in a final prospectus supplement to be filed with the SEC. Analysts maintain a bullish outlook on AVBP, with price targets ranging from $37 to $45 per share. InvestingPro subscribers can access 5 additional exclusive insights about ArriVent’s financial health and growth prospects.

In other recent news, ArriVent BioPharma has reported notable progress in its Phase 1b FURTHER trial for firmonertinib, a drug targeting non-small cell lung cancer (NSCLC) with EGFR PACC mutations. The company revealed a median progression-free survival of 16 months for patients on a 240 mg dose, with a confirmed overall response rate of 68.2%. Additionally, the trial demonstrated a 41% complete response rate in patients with brain metastases. H.C. Wainwright has maintained a Buy rating on ArriVent BioPharma, raising the stock target to $40.00, citing the promising clinical trial results. The firm’s analyst, Robert Burns, noted the drug’s efficacy compared to existing treatments, highlighting its potential in filling a treatment gap for NSCLC patients with specific genetic mutations. ArriVent also announced the appointment of Dr. Merdad Parsey to its Board of Directors, bringing his extensive experience in global clinical development to the company. This addition comes as ArriVent prepares for the potential registration of firmonertinib and advances its antibody drug conjugate pipeline. The company plans to start a global Phase 3 trial, ALPACCA, in 2025 to further evaluate firmonertinib’s potential for accelerated and full approval.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.